Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto
US8203019B2 · kind B2 · utility
2Cited by
1References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 20, 2006 |
| Grant date | Jun 19, 2012 |
| Priority date | — |
| Expiry date | Jul 20, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.